Head and Neck Cancer Market Global Industry Analysis, Size, Share, Growth, Trends, And Forecast 2017 - 2025

Oct 2018| TMR974A| Transparency

Report Highlights

Global Head and Neck Cancer Market: Overview

This report analyzes the current and future scenario of the global head and neck cancer market. Increase in patient population with head and neck cancer, growth of the pharmaceutical industry, improvement in health care infrastructure, and surge in the number of clinical trials are projected to be the major drivers of the global market during the forecast period.

The global head and neck cancer market report comprises an elaborate executive summary, which includes a snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to the segments based on drug class, distribution channel, and region. A detailed qualitative analysis of drivers and restraints of the market, and opportunities has been provided in the market overview section. Additionally, the section comprises competitive matrix and company profiles along with business overview to understand the competitive landscape in the market. This section of the report also provides market attractiveness analysis by region and market share analysis by key players, thereby presenting a thorough analysis of the overall competitive scenario in the global head and neck cancer market.

Global Head and Neck Cancer Market: Key Segments

Based on drug class, the global head and neck cancer market has been segmented into EFGR inhibitors, mitotic inhibitors, anti-PD-1 monoclonal antibodies, and others. The segments have been analyzed based on available drug product used during the treatment of head and neck cancer, cost-effectiveness, and preference for industries. In terms of distribution channel, the global market has been classified into hospital pharmacies, retail pharmacies, and e-commerce. The market size and forecast for each of these segments have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year.

Global Head and Neck Cancer Market: Regional Outlook

In terms of region, the global head and neck cancer market has been segmented into five major regions: North America (U.S. and Canada), Europe (U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (India, China, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (South Africa, GCC Countries, Israel, and Rest of Middle East & Africa). The market size and forecast for each of these regions and the mentioned countries have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year. The research study also covers the competitive scenario in these regions.

Companies Mentioned in Report

The report also profiles major players in the global head and neck cancer market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. The major players profiled in the market report include Sanofi, Pfizer, Eli Lilly and Company, Merck KgaA, Bristol-Myers Squibb Company, Bayer AG, Galera, Fresenius Kabi, and Teva Pharmaceuticals.

The global head and neck cancer market has been segmented as below:

Global Head and Neck Cancer Market, by Drug Class
EGFR Inhibitors
Mitotic Inhibitors
Anti-PD-1 Monoclonal Antibodies
Others
Global Head and Neck Cancer Market, by Distribution Channel
Hospitals Pharmacies
Retail Pharmacies
E-commerce
Global Head and Neck Cancer Market, by Region
North America
U.S.
Canada
Europe
Germany
U.K.
Italy
France
Spain
Rest of Europe
Asia Pacific
India
China
Japan
Australia & New Zealand
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
GCC Countries
South Africa
Israel
Rest of Middle East & Africa

  • Table 1 : Global Head and Neck Cancer (HNC) Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
  • Table 2 : Global Head and Neck Cancer (HNC) Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
  • Table 3 : Global Head and Neck Cancer (HNC) Market Size (US$ Mn) Forecast, by Region, 2016–2026
  • Table 4 : North America Head and Neck Cancer (HNC) Market Size Value (US$ Mn) Forecast, by Country, 2016–2026
  • Table 5 : North America Head and Neck Cancer (HNC) Market Size Value (US$ Mn) Forecast, by Drug Class, 2016–2026
  • Table 6 : North America Head and Neck Cancer (HNC) Market Size (US$ Mn) Forecast, by Distribution Channel,
  • Table 7 : Europe Head and Neck Cancer (HNC) Market Size Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
  • Table 8 : Europe Head and Neck Cancer (HNC) Market Size Value (US$ Mn) Forecast, by Drug Class, 2016–2026
  • Table 9 : Europe Head and Neck Cancer (HNC) Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
  • Table 10 : Asia Pacific Head and Neck Cancer (HNC) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
  • Table 11 : Asia Pacific Head and Neck Cancer (HNC) Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
  • Table 12 : Asia Pacific Head and Neck Cancer (HNC) Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
  • Table 13 : Latin America Head and Neck Cancer (HNC) Market Value (US$ Mn) Forecast, by Country/Sub-region,
  • Table 14 : Latin America Head and Neck Cancer (HNC) Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
  • Table 15 : Latin America Head and Neck Cancer (HNC) Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
  • Table 16 : Middle East & Africa Head and Neck Cancer (HNC) Market Size Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
  • Table 17 : Middle East & Africa Head and Neck Cancer (HNC) Market Size Value (US$ Mn) Forecast, by Drug Class, 2016–2026
  • Table 18 : Middle East & Africa Head and Neck Cancer (HNC) Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
  • Figure 1 : Global Head and Neck Cancer (HNC) Market Size Value (US$ Mn) Forecast, 2016–2026
  • Figure 2 : Global Head and Neck Cancer (HNC) Market Value Share (%), by Drug Class (2017)
  • Figure 3 : Global Head and Neck Cancer (HNC) Market Value Share (%), by Distribution Channel (2017)
  • Figure 4 : Global Head and Neck Cancer (HNC) Market Value Share (%), by Region (2017)
  • Figure 5 : Global Head and Neck Cancer (HNC) Market Value Share (%), by Drug Class, 2018 and 2026
  • Figure 6 : Global Head and Neck Cancer (HNC) Market Attractiveness, by Drug Class, 2018–2026
  • Figure 7 : Global Head and Neck Cancer (HNC) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by EGFR Inhibitors, 2016–2026
  • Figure 8 : Global Head and Neck Cancer (HNC) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Mitotic Inhibitors, 2016–2026
  • Figure 9 : Global Head and Neck Cancer (HNC) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Anti-PD-1 Monoclonal Antibodies, 2016–2026
  • Figure 10 : Global Head and Neck Cancer (HNC) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others,
  • Figure 11 : Global Head and Neck Cancer (HNC) Market Value Share Analysis, by Distribution Channel, 2018 and 2026
  • Figure 12 : Global Head and Neck Cancer (HNC) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by
  • Figure 13 : Global Head and Neck Cancer (HNC) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2016–2026
  • Figure 14 : Global Head and Neck Cancer (HNC) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by E-commerce, 2016–2026
  • Figure 15 : Global Head and Neck Cancer (HNC) Market Attractiveness Analysis, by Distribution Channel, 2018–2026
  • Figure 16 : Global Head and Neck Cancer (HNC) Market Value Share Analysis, by Region, 2018 and 2026
  • Figure 17 : Global Head and Neck Cancer (HNC) Market Attractiveness Analysis, by Region, 2018–2026
  • Figure 18 : North America Head and Neck Cancer (HNC) Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
  • Figure 19 : North America Head and Neck Cancer (HNC) Market Value Share Analysis, by Country, 2018 and 2026
  • Figure 20 : North America Head and Neck Cancer (HNC) Market Attractiveness Analysis, by Country, 2018–2026
  • Figure 21 : North America Head and Neck Cancer (HNC) Market Value Share (%), by Drug Class, 2018 and 2026
  • Figure 22 : North America Head and Neck Cancer (HNC) Market Attractiveness, by Drug Class, 2018–2026
  • Figure 23 : North America Head and Neck Cancer (HNC) Market Value Share Analysis, by Distribution Channel, 2018 and 2026
  • Figure 24 : North America Head and Neck Cancer (HNC) Market Attractiveness Analysis, by Distribution Channel, 2018-2026
  • Figure 25 : Europe Head and Neck Cancer (HNC) Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
  • Figure 26 : Europe Head and Neck Cancer (HNC) Market Value Share Analysis, by Country/Sub-region, 2018 and 2026
  • Figure 27 : Europe Head and Neck Cancer (HNC) Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
  • Figure 28 : Europe Head and Neck Cancer (HNC) Market Value Share (%), by Drug Class, 2018 and 2026
  • Figure 29 : Europe Head and Neck Cancer (HNC) Market Attractiveness, by Drug Class, 2018–2026
  • Figure 30 : Europe Head and Neck Cancer (HNC) Market Value Share Analysis, by Distribution Channel, 2018 and 2026
  • Figure 31 : Europe Head and Neck Cancer (HNC) Market Attractiveness Analysis, by Distribution Channel, 2018-2026
  • Figure 32 : Asia Pacific Head and Neck Cancer (HNC) Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
  • Figure 33 : Asia Pacific Head and Neck Cancer (HNC) Market Value Share Analysis, by Country/Sub-region, 2018 and 2026
  • Figure 34 : Asia Pacific Head and Neck Cancer (HNC) Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
  • Figure 35 : Asia Pacific Head and Neck Cancer (HNC) Market Value Share (%), by Drug Class, 2018 and 2026
  • Figure 36 : Asia Pacific Head and Neck Cancer (HNC) Market Attractiveness, by Drug Class, 2018–2026
  • Figure 37 : Asia Pacific Head and Neck Cancer (HNC) Market Value Share Analysis, by Distribution Channel, 2018 and 2026
  • Figure 38 : Asia Pacific Head and Neck Cancer (HNC) Market Attractiveness Analysis, by Distribution Channel, 2018-2026
  • Figure 39 : Latin America Head and Neck Cancer (HNC) Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
  • Figure 40 : Latin America Head and Neck Cancer (HNC) Market Value Share Analysis, by Country/Sub-region, 2018 and 2026
  • Figure 41 : Latin America Head and Neck Cancer (HNC) Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
  • Figure 42 : Latin America Head and Neck Cancer (HNC) Market Value Share (%), by Drug Class, 2018 and 2026
  • Figure 43 : Latin America Head and Neck Cancer (HNC) Market Attractiveness, by Drug Class, 2018–2026
  • Figure 44 : Latin America Head and Neck Cancer (HNC) Market Value Share Analysis, by Distribution Channel, 2018 and 2026
  • Figure 45 : Latin America Head and Neck Cancer (HNC) Market Attractiveness Analysis, by Distribution Channel, 2018-2026
  • Figure 46 : Middle East & Africa Head and Neck Cancer (HNC) Market Size (US$ Mn) Forecast, 2016–2026
  • Figure 47 : Middle East & Africa Head and Neck Cancer (HNC) Market Value Share Analysis, by Country/Sub-region, 2018 and 2026
  • Figure 48 : Middle East & Africa Head and Neck Cancer (HNC) Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
  • Figure 49 : Middle East & Africa Head and Neck Cancer (HNC) Market Value Share (%), by Drug Class, 2018 and 2026
  • Figure 50 : Middle East & Africa Head and Neck Cancer (HNC) Market Attractiveness, by Drug Class, 2018–2026
  • Figure 51 : Middle East & Africa Head and Neck Cancer (HNC) Market Value Share Analysis, by Distribution Channel, 2018 and 2026
  • Figure 52 : Middle East & Africa Head and Neck Cancer (HNC) Market Attractiveness Analysis, by Distribution Channel, 2018–2026
  • Figure 53 : Global Head and Neck Cancer (HNC) Market Share, by Company, 2017
  • Figure 54 : AstraZeneca Oncology Business Revenue (US$ Bn) & Y-o-Y Growth (%), 2014 –2017
  • Figure 55 : AstraZeneca R&D in Oncology Segment Revenue (US$ Bn) & Y-o-Y Growth (%), 2014 –2017
  • Figure 56 : AstraZeneca's Oncology Business Segment Revenue (% Share), by Region, 2017
  • Figure 57 : Eli Lilly and Company Revenue (US$ Bn) & Y-o-Y Growth (%), 2014–2017
  • Figure 58 : Eli Lilly and Company Breakdown of Net Sales, by Region, 2017
  • Figure 59 : Eli Lilly and Company Breakdown of Net Sales, by Business Segment, 2017
  • Figure 60 : Eli Lilly and Company Research and Development Cost, 2016 and 2017 (US$ Mn)
  • Figure 61 : Pfizer, Inc.’s Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2017
  • Figure 62 : Pfizer, Inc.’s Oncology Business Segment Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2017
  • Figure 64 : Pfizer, Inc.’s Revenue (% Share), by Business Segment, 2017
  • Figure 64 : Pfizer, Inc.’s Revenue (% Share), by Business Segment, 2017
  • Figure 66 : Novartis AG Revenue (US$ Bn) & Y-o-Y Growth (%), 2014–2017
  • Figure 67 : Novartis AG Oncology Business Segment Revenue (US$ Mn) & Y-o-Y Growth (%), 2015–2017
  • Figure 68 : Novartis AG’s Net Sales (% Share), by Business Segment, 2017
  • Figure 69 : Novartis AG’s Net Sales (% Share), by Region, 2017
  • Figure 70 : Bristol-Myers Squibb Company Revenue (US$ Bn), 2014-2017
  • Figure 71 : Bristol-Myers Squibb Company R&D Expenditure (US$ Bn), 2015- 2017
  • Figure 72 : Bristol-Myers Squibb Company Revenue, by Geography, 2017
  • Figure 73 : Bayer AG Pharmaceutical Business Segment Revenue (US$ Bn), 2015-2017
  • Figure 74 : Bayer AG Pharmaceutical Business Segment R&D Expenditure (US$ Bn), 2015-2017
  • Figure 75 : Bayer AG Pharmaceutical Business Segment Revenue, by Geography (2017)
  • Figure 76 : F. Hoffmann-La Roche Ltd. Oncology Segment Revenue (US$ Bn), 2015–2017
  • Figure 77 : F. Hoffmann-La Roche Ltd. Pharmaceutical Segment R&D Expenditure (US$ Bn), 2015–2017
  • Figure 78 : F. Hoffmann-La Roche Ltd. Pharmaceutical Segment Revenue, by Specialty (2017)
  • Figure 79 : F. Hoffmann-La Roche Ltd. Pharmaceutical Segment Revenue, by Region (2017)
  • Figure 80 : Sanofi Revenue (US$ Bn), 2014-2017
  • Figure 81 : Sanofi Regional Sales Breakdown (%), 2017
  • Figure 82 : Teva Pharmaceutical Industries Ltd. Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2017
  • Figure 83 : Teva Pharmaceutical Industries Ltd. Segmental Revenue (US$ Bn), 2017
  • Figure 84 : Fresenius SE & Co. KGaA Revenue (US$ Bn) & Y-o-Y Growth (%), 2014–2017
  • Figure 85 : Fresenius SE & Co. KGaA Breakdown of Net Sales (%), by Business Segment, 2017
  • Figure 86 : Merck KGaA Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2017
  • Figure 87 : Merck KGaA Revenue, by Geography (%), 2017
  • Figure 88 : Merck KGaA Revenue, by Business Segment (%), 2014–2017

Leaders in analytics, research and advisory services for Fortune 500 companies, scores of high potential startups, and financial institutions. Our success stories have proven why we are a prominent provider of a cutting-edge syndicated and customized research services. Leverage the best of our seasoned research analysts who had a keen interest and enviable expertise of almost 4 million hours in global, regional, and local market intelligence.

Why BCC Research?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
CUSTOM RESEARCH

Need a custom data table, graph or complete report? Tell us more.

Contact Us
Share This Report